Published in J Clin Oncol on December 01, 2007
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res (2012) 1.08
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res (2010) 1.01
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer (2011) 0.98
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med (2014) 0.95
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer (2009) 0.93
Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci (2009) 0.92
Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res (2012) 0.90
Update on primary head and neck mucosal melanoma. Head Neck (2015) 0.88
Systematic review of diagnostic accuracy of reflectance confocal microscopy for melanoma diagnosis in patients with clinically equivocal skin lesions. Dermatol Pract Concept (2013) 0.88
Vaginal primary malignant melanoma: a rare and aggressive tumor. Case Rep Obstet Gynecol (2013) 0.87
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol (2011) 0.82
Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp Oncol (Pozn) (2013) 0.82
Malignant melanoma of the head and neck: a brief review of pathophysiology, current staging, and management. Ochsner J (2008) 0.80
Survival in Sinonasal Melanoma: A Meta-analysis. J Neurol Surg B Skull Base (2012) 0.80
Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One (2014) 0.80
Novel dendritic cell-based vaccination in late stage melanoma. Hum Vaccin Immunother (2014) 0.79
ETM study of electroporation influence on cell morphology in human malignant melanoma and human primary gingival fibroblast cells. Asian Pac J Trop Biomed (2011) 0.79
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Int J Cancer (2013) 0.79
Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol (2013) 0.79
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol (2010) 0.79
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene (2015) 0.79
Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract (2011) 0.79
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. J Transl Med (2010) 0.77
Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma. Medicine (Baltimore) (2016) 0.77
Role of IL-2 in cancer immunotherapy. Oncoimmunology (2016) 0.76
Melanoma immunotherapy. Cancer Biol Ther (2014) 0.76
Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther (2015) 0.76
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine (Baltimore) (2016) 0.75
Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression. Oncol Lett (2017) 0.75
Lung cancer: First-line immunotherapy in lung cancer - taking the first step. Nat Rev Clin Oncol (2016) 0.75
IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma. PLoS One (2014) 0.75
Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. Ann Surg Oncol (2014) 0.75
Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature. In Vivo (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol (2010) 3.56
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol (2013) 2.74
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26
Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol (2013) 2.22
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Identifying melanomas in primary care: can we do better? BMJ (2012) 2.01
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol (2009) 1.96
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
PEPtalk: postexposure prophylaxis against varicella in children with cancer. Arch Dis Child (2011) 1.91
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol (2012) 1.91
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood (2005) 1.85
Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (2012) 1.80
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol (2010) 1.70
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood (2005) 1.70
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol (2009) 1.52
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol (2013) 1.52
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol (2005) 1.50
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol (2011) 1.44
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal (2014) 1.44
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol (2002) 1.40
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood (2013) 1.36
Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ (2012) 1.35
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol (2009) 1.30
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol (2013) 1.28
Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant (2003) 1.23
Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers. J Pain Symptom Manage (2012) 1.20
Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev (2012) 1.16
Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (2013) 1.14
Management of small cell lung cancer: recent developments for optimal care. Drugs (2012) 1.13
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol (2010) 1.12
Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. J Thorac Oncol (2011) 1.12
Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ (2003) 1.12
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol (2006) 1.04
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer (2010) 1.03
A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol (2010) 1.02
Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs (2005) 1.01
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ (2004) 0.99
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother (2009) 0.99
Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Res (2014) 0.96
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. Br J Haematol (2012) 0.95
Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (2012) 0.94
Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord (2011) 0.92
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes (2012) 0.92
Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. J Invest Dermatol (2002) 0.91
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev (2010) 0.90
Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol (2006) 0.89
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2010) 0.89
Modern management of small-cell lung cancer. Drugs (2007) 0.88
Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation (2009) 0.88
Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. J Evid Based Med (2009) 0.88
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. Lung Cancer (2011) 0.88
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer (2008) 0.87
Physiotherapy for Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev (2014) 0.86
Evaluating drug treatments for Parkinson's disease: how good are the trials? BMJ (2002) 0.86
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer (2011) 0.85
Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood (2012) 0.85
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer (2011) 0.85
Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. Clin Lung Cancer (2005) 0.84
Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Rev Anticancer Ther (2012) 0.84
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Res (2009) 0.83
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist (2012) 0.83
Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer (2012) 0.82
A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol. BMC Neurol (2012) 0.81
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res (2015) 0.81
Home-based reach-to-grasp training for people after stroke: study protocol for a feasibility randomized controlled trial. Trials (2013) 0.80
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther (2004) 0.80
Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. Support Care Cancer (2012) 0.80
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer (2012) 0.80
Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) (2002) 0.79
Interferon as adjuvant treatment for melanoma. Lancet (2002) 0.79
Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? Drugs (2006) 0.79